The National Institutes of Health has launched a global clinical trial to test a potential COVID-19 treatment that combines remdesivir with a highly concentrated antibody solution. The phase 3 trial will enroll 500 hospitalized adults who have had COVID-19 symptoms for 12 or fewer days and no serious organ dysfunction, and compare their health status after the combination treatment with participants receiving remdesivir and a placebo. The agency also announced a research network to study the immune response to COVID-19 and increase antibody testing capacity.

Related News Articles

Headline
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Fusce congue lorem nisl, ac dapibus dui vestibulum ut. Vivamus egestas at ipsum eget posuere.…
Headline
Moderna Inc. today announced that its mRNA-1273 vaccine candidate against COVID-19 is 94.5% effective, according to early data. The candidate is currently…
Headline
As of Nov. 6, about 60% of the nation’s retail pharmacies have agreed to participate in a federal program to administer COVID-19 vaccines at no cost to…
Perspective
“Don’t let perfect be the enemy of the good” is a quote credited to the French writer and thinker Voltaire. Although he died in 1778, that phrase is very…
Headline
To continue amplifying the important message of protecting against both the flu and COVID-19, AHA’s Wear A Mask and United Against the Flu campaigns today…
Headline
The Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response has released guidance on considerations for health…